EGFR and non-small cell lung carcinoma: In July 2022, Elamin et al. published a study of 50 patients with EGFR exon 20 point mutation-positive NSCLC who underwent treatment with poziotinib and achieved the primary-end point of an objective response rate (ORR) of 32% and mPFS of 5.5 months; however, clinical activity varied depending on near or far loop insertion of the point mutation47.